Business Wire

Equazen ® Reaffirms Its Commitment to Uncompromising Quality and Sustainability in Omegas Supplements

26.6.2025 09:00:00 EEST | Business Wire | Press release

Share

SFI Health™EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, highlights today its ongoing commitment to delivering the highest standard of quality for Equazen®, the company’s global science-based food supplement brand designed to nourish, enhance and support the brain’s potential.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625554235/en/

Equazen® continues to set the benchmark for excellence at every step of the value chain

At SFI Health™, quality is more than a requirement—it is a mission. The company is committed to enhancing people’s well-being by developing natural supplements that combine passion for nature-based healthcare, science, state-of-the-art production standards and sustainability, from ingredient sourcing to the final product reaching the patient.

In particular, with over 25 years of trust built across multiple markets, Equazen®'s excellence is built on five core pillars:

  • Ingredients Sourcing: Equazen®’s story begins in the sea, with responsibly sourced fish oil rich in essential Omega-3 fatty acids EPA and DHA, paired with cold-pressed evening primrose and borage seeds oils for Omega-6 (GLA). Every ingredient is carefully selected from certified suppliers, processed using validated methods ensuring purity and safety as well as full traceability in compliance with European Pharmacopoeia regulations. Besides, Equazen® suppliers are part of the IFFO, the international marine ingredients organization, promoting responsible sourcing and high-quality manufacturing in the industry of fish oil.
  • Manufacturing & Supply Chain: Equazen® is produced under strict GMP standards, with each fish oil batch undergoing rigorous quality testing. All manufacturers adhere to recognized food safety systems, including HACCP and FDA registration. The supply chain is equally controlled—from packaging to transport—to protect product integrity till it reaches consumers. In addition, Equazen®’s suppliers are members of GOED (Global Organization for EPA and DHA Omega-3s), a respected international association setting high ethical and quality standards for the Omega-3 industry.
  • Science-backed innovation: Equazen® products feature a unique and carefully balanced combination of essential fatty acids (Omega 3 and Omega 6), designed to support cognitive needs. Since its inception in 1999, Equazen® products’ benefits for the human brain have been proven in over 15 pre-clinical and clinical investigations. In addition, ongoing collaborations with global experts and research institutions further strengthen the scientific foundation.
  • Customer focus: Understanding and responding to consumer needs is key to Equazen®’s success. Feedback from parents, healthcare professionals, and consumers shapes product development and ongoing support. The brand also offers personalized guidance and educational resources to optimize usage.
  • Sustainability: Equazen® also prioritizes environmental responsibility with sustainable production processes designed to minimize environmental impact. Its fish oil is sourced from regulated, sustainable fisheries and is a by-product of the fishmeal industry—ensuring no additional fish are caught for production. In addition, Equazen® fish oils are certified by Friends of the Sea®, a globally recognized independent body guaranteeing responsible sourcing, full traceability, and environmental stewardship.

“Our mission with Equazen® is to provide natural supplements that parents and caregivers can trust to support cognitive needs and the health of human brain,” said Matthew Brabazon, General Manager at SFI Health™ EMEA. “This is made possible only through ethical sourcing, advanced manufacturing, and robust scientific validation.”

As market demands evolve, Equazen® remains dedicated to pushing quality standards further at every step of the value chain to offer best-in-class solutions for optimal cognitive health. Consumers can trust that every product reflects a passion for health, innovation, and sustainability.

About SFI Health™

SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.

Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.

An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.

SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.

For more information, go to sfihealth.com or follow us SFI Health on LinkedIn.

About Equazen®

Equazen® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages.

Each product of the Equazen® range contains a balanced unique combination of essential fatty acids (Omega-3 and Omega-6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.

Equazen® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.

Currently marketed in 30 countries globally, Equazen® is widely recommended by healthcare professionals and trusted by families for the last 25 years.

Equazen® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.

For more info visit www.equazen.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250625554235/en/

Contacts

For more information

SFI Health™ EMEA Contact
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Philip Morris International Publishes Inaugural Taskforce on Nature-related Financial Disclosures Report22.9.2026 12:00:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today published its inaugural Taskforce on Nature-related Financial Disclosures (TNFD) Report, providing shareholders and other stakeholders with its most comprehensive assessment to date of nature-related dependencies, impacts, risks, and opportunities (DIROs) across the company’s global value chain. As an early adopter of the TNFD recommendations, PMI’s TNFD Report supports the company’s efforts to sharpen its understanding of how natural capital considerations influence business resilience and decision-making over time, while contributing to emerging practices in nature-related disclosure. Nature is one of the six strategic priorities that define PMI’s Value Plan 2030+, the company’s framework for long-term sustainable value creation, alongside Consumers, Circularity, Climate, Our Workforce, Workers in Our Value Chain. The TNFD Report follows the release of PMI’s 2025 Climate Transition Plan, prepared in line with the TCFD framework,

ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 10:00:00 EEST | Press release

ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup

Regnology Research Maps Route From AI Pilots to Production in Regulatory Reporting22.9.2026 09:33:00 EEST | Press release

Regnology, a leader in regulatory, risk, tax and finance reporting technology, today published “The Agentic Gap: From Control to Intelligence in Regulatory Reporting”, accompanied by a video foreword from Chief Executive Officer Rob Mackay. The global study sets out where agentic AI can take on meaningful operational load today, and gives institutions a practical roadmap from isolated pilots into scaled production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921218912/en/ The research finds an industry already mobilizing. 87% of respondents are exploring, piloting or embedding AI in operations, and only 13% report no current plan. The constraint is a shared one. Embedded, production-level use sits between 8% and 15% at every institution tier, and 16% of respondents overall have reached it, with 89% of financial institutions yet to get there. Resources buy experimentation, but production use is earned on the same terms

Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 2028 1 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements: Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio

OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 08:00:00 EEST | Press release

OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of 96% over each program’s original media combinations*. In separate internal studies, OPM-CHO media demonstrated lot-to-lot variability below 5%.* As patent expirations create new opportunities for biosimilar development, achieving a pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye